Pfizer stock forecast
Pfizer's weighted scenario is $26.44 by October 2027, implying −0% return. It hinges on non-COVID sales supporting guidance and cash after dividends and capital spending improving.
Where could Pfizer's shares be by October 2029?
The verdict is a possible $29.42 by October 2029 and a 23% total return, hinging on replacement products and cash generation offsetting COVID decline and patent losses. Management guides to 2026 revenue of $60,500–$62,500 million and adjusted diluted EPS of $2.80–$3.00. It targets $5,700 million of net cost savings by year-end 2026, against about $17 billion of annual revenue erosion by 2030 as products lose exclusivity, meaning their legal protections expire.
The bear endpoint is $13.60 and the bull endpoint is $49.82. Today’s price is $28.30. The probabilities are 28% bear, 52% base and 20% bull.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 28 % | 19.97 (-23 %) | 16.52 (-29 %) | 13.60 (-34 %) |
| Base | 52 % | 26.80 (+1 %) | 27.47 (+9 %) | 30.10 (+25 %) |
| Bull | 20 % | 34.55 (+28 %) | 41.45 (+59 %) | 49.82 (+96 %) |
| Weighted | 100 % | 26.44 (-0 %) | 27.20 (+8 %) | 29.42 (+23 %) |
What this means. The weighted row is the probability-based average value across the bear, base, and bull cases, not a separate forecast.
What has to go right or wrong for Pfizer?
The base revenue path starts at $62,000M and reaches $62,500M next. It finishes at $64,000M. Margins begin at 26% and end at 27%, producing earnings of $16,120M initially and $16,560M next; final earnings are $17,280M. This sits near the 2026 guidance anchor, while giving partial credit to high-single-digit growth after 2028. Recent quarterly beats support the starting point, but the history of sharp earnings swings argues against a faster climb.
The bear path starts at $59,500M and falls to $57,500M. Final revenue is $56,000M. Margins start at 24% and fall to 22%, ending at 20%, producing the earnings shown in the table. COVID normalization, Ibrance and Xtandi pressure, Eliquis risk and failed trials justify the decline. The bull path starts at $64,000M and reaches $68,000M. It ends at $73,000M. Margins rise from 28% to 30% as launches, savings and product mix improve.
| October 2027 | October 2028 | October 2029 | |
|---|---|---|---|
| Earnings | 16,120 (14,280 / 17,920) | 16,560 (12,650 / 19,720) | 17,280 (11,200 / 21,900) |
| Shares (millions) | 5,714 (5,722 / 5,705) | 5,728 (5,744 / 5,710) | 5,742 (5,766 / 5,715) |
| Dividends per share | 1.72 (1.72 / 1.76) | 1.76 (1.72 / 1.84) | 1.80 (1.55 / 1.92) |
| Price to earnings | 9.50 (8.00 / 11.00) | 9.50 (7.50 / 12.00) | 10.00 (7.00 / 13.00) |
How much cash does Pfizer really make?
Cash from operations was 11,704 in 2025. After capital spending of 2,629, free cash flow was 9,075. The figure recovered from 2023, but it remained far below the pandemic-era cash rate.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 11,704 | 12,744 | 8,700 | 29,267 | 32,922 |
| − Capital spending | 2,629 | 2,909 | 3,907 | 3,236 | 2,711 |
| = Free cash flow | 9,075 | 9,835 | 4,793 | 26,031 | 30,211 |
| − Stock pay | 799 | 877 | 525 | 872 | 1,182 |
| = Real free cash flow | 8,276 | 8,958 | 4,268 | 25,159 | 29,029 |
What this means. The blank working-capital rows do not mean zero; they mean that year's cash-flow effect was not shown separately in this table.